BIO-106 + pembrolizumab

BIO-106 + pembrolizumab is a combination drug regimen under clinical investigation for the treatment of advanced or metastatic solid tumors. **BIO-106** is an anti-Trop-2 antibody-drug conjugate (ADC) designed to target Trop-2, a cell-surface protein overexpressed in multiple tumor types including triple-negative breast cancer (TNBC), hormone receptor positive/human epidermal growth factor receptor 2 negative metastatic breast cancer (HR+/HER2- mBC), and non-small cell lung cancer (NSCLC)[7]. **Pembrolizumab** (Keytruda) is a monoclonal antibody that inhibits programmed cell death protein 1 (PD-1), a checkpoint on immune cells, thereby enhancing the immune system’s ability to attack cancer cells[3][4]. The combination is hypothesized to offer synergistic effects by directly delivering cytotoxic payloads to Trop-2 expressing tumor cells while unleashing immune-mediated anti-tumor activity via PD-1 blockade.

Other names

MK-3475 (for pembrolizumab)